CRISPR Therapeutics (NASDAQ:CRSP) Given New $47.00 Price Target at The Goldman Sachs Group
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by equities research analysts at The Goldman Sachs Group from $53.00 to $47.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 31.95% […]
More Stories
Promising Toy Stocks To Keep An Eye On – September 21st
Costco Wholesale, Walmart, Target, Kroger, Take-Two Interactive Software, Dollar Tree, and Dollar General are the seven Toy stocks to watch...
What is Noble Financial’s Estimate for RAIL Q1 Earnings?
Freightcar America, Inc. (NASDAQ:RAIL – Free Report) – Investment analysts at Noble Financial decreased their Q1 2026 earnings per share...
HC Wainwright Raises Earnings Estimates for Innate Pharma
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA – Free Report) – Equities researchers at HC Wainwright boosted their FY2025 earnings estimates...
What is B. Riley’s Forecast for ADTRAN Q3 Earnings?
ADTRAN Holdings, Inc. (NASDAQ:ADTN – Free Report) – Stock analysts at B. Riley issued their Q3 2025 earnings estimates for...
IREN Target of Unusually High Options Trading (NASDAQ:IREN)
IREN Limited (NASDAQ:IREN – Get Free Report) saw unusually large options trading activity on Monday. Investors acquired 193,501 call options...
Tesla (NASDAQ:TSLA) Trading Up 1.9% on Analyst Upgrade
Tesla, Inc. (NASDAQ:TSLA – Get Free Report)’s stock price traded up 1.9% during trading on Monday after CICC Research raised...